The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Covid-19 in pharma: COVID recombinant spike proteins. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
COVID recombinant spike proteins is a key innovation area in Covid-19
COVID recombinant spike protein is a glycoprotein that mediates membrane fusion and viral entry. The full-length S protein consists of an extracellular domain (ECD), divided into a S1 and S2 subunit, a transmembrane domain and a short cytoplasmic domain. Recombinant spike-based proteins were developed by immunization of animal models to evaluate these subunit-based antigens for potential use as vaccine candidates.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 260+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of COVID recombinant spike proteins.
Key players in COVID recombinant spike proteins – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to COVID recombinant spike proteins
|Company||Total patents (2010 - 2022)||Premium intelligence on the world's largest companies|
|Sanofi||159||Unlock Company Profile|
|C. H. Boehringer Sohn||140||Unlock Company Profile|
|Takeda Pharmaceutical||95||Unlock Company Profile|
|Centre National de la Recherche Scientifique||83||Unlock Company Profile|
|Merck||80||Unlock Company Profile|
|Zoetis||70||Unlock Company Profile|
|Novavax||58||Unlock Company Profile|
|US Department of Health and Human Services||52||Unlock Company Profile|
|Moderna||51||Unlock Company Profile|
|Oswaldo Cruz Foundation||50||Unlock Company Profile|
|Johnson & Johnson||49||Unlock Company Profile|
|Curevac||42||Unlock Company Profile|
|Regeneron Pharmaceuticals||40||Unlock Company Profile|
|GSK||30||Unlock Company Profile|
|Codagenix||29||Unlock Company Profile|
|U.S. Department of Defence||26||Unlock Company Profile|
|Academia Sinica||26||Unlock Company Profile|
|FDS Pharma||25||Unlock Company Profile|
|Excivion||23||Unlock Company Profile|
|New York Blood Center||23||Unlock Company Profile|
|Dynavax Technologies||22||Unlock Company Profile|
|Theravectys||22||Unlock Company Profile|
|CareGroup||19||Unlock Company Profile|
|CanSino Biologics||19||Unlock Company Profile|
|Guangzhou Anjie Biomedical Technology||19||Unlock Company Profile|
|Medigen Biotechnology||19||Unlock Company Profile|
|Inovio Pharmaceuticals||18||Unlock Company Profile|
|F. Hoffmann-La Roche||18||Unlock Company Profile|
|Reber Genetics||18||Unlock Company Profile|
|Mayo Clinic||17||Unlock Company Profile|
|International Centre for Genetic Engineering and Biotechnology||17||Unlock Company Profile|
|Valneva||17||Unlock Company Profile|
|Altimmune||16||Unlock Company Profile|
|BioNTech||15||Unlock Company Profile|
|Arcturus Therapeutics||15||Unlock Company Profile|
|RNAimmune Inc||14||Unlock Company Profile|
|Akston Biosciences||14||Unlock Company Profile|
|PerkinElmer||13||Unlock Company Profile|
|The United States Of America||13||Unlock Company Profile|
|Etubics||12||Unlock Company Profile|
|Greffex||12||Unlock Company Profile|
|Providence Therapeutics||12||Unlock Company Profile|
|EpiVax||12||Unlock Company Profile|
|Meissa Vaccines||12||Unlock Company Profile|
|Suzhou Abogen Biosciences||11||Unlock Company Profile|
|Erasmus MC||11||Unlock Company Profile|
|Daiichi Sankyo||11||Unlock Company Profile|
|A H S Hospital||11||Unlock Company Profile|
|NantWorks||11||Unlock Company Profile|
|Gritstone Bio||11||Unlock Company Profile|
Source: GlobalData Patent Analytics
Sanofi is one of the leading patent filers in COVID recombinant spike proteins. Sanofi is a major pharmaceutical company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis, human vaccines for protection against various bacterial and viral diseases, and other diseases. VidPrevtyn Beta is one of its approved Covid-19 vaccines, which acts by targeting 2019 Novel corona Virus Spike Glycoprotein (E2 or Peplomer Protein or S). C. H. Boehringer Sohn and Takeda Pharmaceutical are some of the other key patent filers in COVID recombinant spike proteins.
In terms of application diversity, Regeneron Pharmaceuticals leads the pack, while Akston Biosciences and Excivion stood in the second and third positions, respectively. By means of geographic reach, S Curevac held the top position, followed by Excivion and Theravectys.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.